Also prevent damage from UV rays, regenerate and repair tissues
Yamada T, Sato S, Sotoyama Y, Orba Y, Sawa H, Yamauchi H, et al
doi: 10.1016/j.febslet.2010.12.001 198 LinTChenYDingZLuoGLiuJShenJ
PMID: 42249138, DOI: 10.1038/s41591-026-04476-6.Peer-Reviewed Original ResearchAltmetricConceptsPlacebo-controlled phase 2b trialGlucagon-like peptide-1 receptor agonistsObesity treatmentPeptide-1 receptor agonistsTreatment-related discontinuationsDouble-blind periodDrug-induced liver injuryPhase 2b trialOpen-label extensionDouble-blind studyGLP-1RA classDose interruptionTolerability profileDouble-blindPlacebo-ControlledGastrointestinal eventsGLP1-RAPrimary endpointReceptor agonistsGLP-1RALiver injuryInterim analysisObesityLS meanWeight loss 2637-P: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial LINGVAY I, KUSHNER R, JASTREBOFF A , GERTSIK L, LIU M, CIVITARESE A, JU C, BUTCHER J, YUE H, BARTH A, COLL B